Document Detail

A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
MedLine Citation:
PMID:  16967785     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To compare the efficacy of low (50 mCi) and high dose (100 mCi) Iodine-131 in ablation of differentiated thyroid cancer remnants. METHODS: Baseline serum thyroglobulin (sTg), thyroglobulin antibody (Tg Ab) and diagnostic whole body iodine scan with 2 mCi of I-131 were performed in each individual. After 6 months serum Tg, Tg Ab (of-thyroxin) and WB iodine scan with 10 mCi of I-131 were done to assess the efficacy of the low and high dose of I-131. Iodine ablative therapy (IAT) was considered successful (complete ablation) if the I-131 whole body scan was negative and sTg level was undetectable. In case of positive scan and/or sTg level detectable the patient was considered as unsuccessfully/partially ablated. RESULTS: In group A, (high dose) successful IAT was seen in 12/20 (60%) patients. Of these 5/7 (71%) had follicular Carcinoma on histopathology and 7/13 (54%) had papillary Ca. In group B, (low dose) successful IAT was seen in 8/20 (40%) patients, out of which 3/10 (30%) had follicular Carcinoma on histopathology and had successful IAT. 5/10 (50%) patients with papillary Carcinoma had successful IAT. As far as histopathology is concerned, in group A, response to high dose I-131 was better in follicular type than papillary type. Whereas in group B, response to low dose I-131 was better in patients with papillary type than follicular. CONCLUSION: 100 mCi of radioactive Iodine-131 (I-131) is a more effective therapeutic dose than 50 mCi (I-131) in the treatment of differentiated thyroid cancer remnants. Furthermore, follicular Carcinoma respond better to 100 mCi I-131 than 50 mCi while papillary Carcinoma showed an almost equal response to both.
Maseeh uz Zaman; Rafia Toor; Shahid Kamal; Minhaj Maqbool; Salman Habib; Khalid Niaz
Related Documents :
10858675 - Medullary thyroid carcinoma in northern ireland, 1967-1997.
8487055 - Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not...
8270035 - Anaplastic carcinoma of the thyroid.
15108075 - Prognostic factors of anaplastic thyroid carcinoma.
9815725 - Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
2573955 - The surgical treatment of gastrinoma in men i syndrome patients.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  JPMA. The Journal of the Pakistan Medical Association     Volume:  56     ISSN:  0030-9982     ISO Abbreviation:  J Pak Med Assoc     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-09-13     Completed Date:  2007-05-30     Revised Date:  2008-02-12    
Medline Journal Info:
Nlm Unique ID:  7501162     Medline TA:  J Pak Med Assoc     Country:  Pakistan    
Other Details:
Languages:  eng     Pagination:  353-6     Citation Subset:  IM    
Karachi Institute of Radiotherapy and Neuclear Medicine, Jinnah Postgraduate Medical Centre.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma, Follicular / blood,  radiotherapy*
Carcinoma, Papillary / blood,  radiotherapy*
Combined Modality Therapy
Dose-Response Relationship, Radiation
Iodine Radioisotopes / therapeutic use*
Neoplasm, Residual
Thyroglobulin / blood
Thyroid Neoplasms / blood,  radiotherapy*
Reg. No./Substance:
0/Iodine Radioisotopes; 9010-34-8/Thyroglobulin
Comment In:
J Pak Med Assoc. 2007 Dec;57(12):622; author reply 622-3   [PMID:  18173052 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Identifying needs and barriers to diabetes education in patients with diabetes.
Next Document:  Appropriate and inappropriate use of fresh frozen plasma.